SAGA Diagnostics

SAGA Diagnostics is a personalised cancer diagnostics and disease monitoring company founded in Lund, 2016, with the mission to intercept cancer at the earliest stages when it’s most treatable. SAGA is focused on ultra-sensitive detection of Molecular Residual Disease (MRD) empowering treatment decisions with greater insight and confidence.

Its flagship test, Pathlight™, is a personalised, blood-based MRD assay built on patient-specific structural variants, enabling best-in-class sensitivity, specificity, and shorter lead times. Commercially available in the U.S. across multiple cancer types and supports both clinical care and drug development.

In May 2026, SAGA Diagnostics was acquired by Roche, with its technology integrated into Foundation Medicine. The acquisition was the first exit from FSG Fund II.

FSG press releases: FSG Fund II Completes First Exit as Roche Acquires SAGA Diagnostics and FSG Invests in SAGA Diagnostics to Advance Precision Cancer Diagnostics